Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells

Abstract Glioblastoma (GBM) is the most aggressive primary brain tumor with a median survival of less than 15 months, emphasizing the need for better treatments. Immunotherapy as a treatment for improving or aiding the patient’s own immune defense to target the tumor has been suggested for GBM. A ra...

Descripción completa

Detalles Bibliográficos
Autores principales: Wenger, Anna, Werlenius, Katja, Hallner, Alexander, Bergh Thorén, Fredrik, Farahmand, Dan, Tisell, Magnus, Smits, Anja, Rydenhag, Bertil, Jakola, Asgeir S., Carén, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715204/
https://www.ncbi.nlm.nih.gov/pubmed/29190492
http://dx.doi.org/10.1016/j.neo.2017.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715204/
https://www.ncbi.nlm.nih.gov/pubmed/29190492
http://dx.doi.org/10.1016/j.neo.2017.10.006

Ejemplares similares